KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $1.4 million.

  • Rigel Pharmaceuticals' Other Non-Current Assets fell 75.49% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 75.49%. This contributed to the annual value of $1.4 million for FY2024, which is 53.03% down from last year.
  • Rigel Pharmaceuticals' Other Non-Current Assets amounted to $1.4 million in FY2024, which was down 53.03% from $3.1 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Other Non-Current Assets registered a high of $3.1 million during FY2023, and its lowest value of $640,000 during FY2022.
  • Its 3-year average for Other Non-Current Assets is $1.7 million, with a median of $1.4 million in 2024.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 377.34% in 2023, then slumped by 53.03% in 2024.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Other Non-Current Assets stood at $824,000 in 2020, then grew by 18.20% to $974,000 in 2021, then slumped by 34.29% to $640,000 in 2022, then skyrocketed by 377.34% to $3.1 million in 2023, then slumped by 53.03% to $1.4 million in 2024.